Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer

Cancer Research

Volumn 74, Issue 13, 2014, Pages 3399-3407

  Jiang, Yi Zhou ^a   Yu, Ke Da ^a   Bao, Jing ^a   Peng, Wen Ting ^a   Shao, Zhi Ming ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; EXOME; FEMALE; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; LOSS OF SOMATIC MUTATION; MAJOR CLINICAL STUDY; MILLER PAYNE SCORE; MULTIPLE CYCLE TREATMENT; MUTATION RATE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PIK3CA GENE; PRIORITY JOURNAL; SCORING SYSTEM; SEQUENCE ANALYSIS; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BREAST NEOPLASMS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROSTAGLANDIN; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903973462     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0092     Document Type: Article

References (36)

1. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:353-60.
2. Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H. Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 2004;10:6418-31.
3. Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 2002;8:461-8.
4. Lee SC, Xu X, Lim YW, Iau P, Sukri N, Lim SE, et al. Chemotherapyinduced tumor gene expression changes in human breast cancers. Pharmacogenet Genomics 2009;19:181-92.
5. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-9.
6. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-4.
7. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
8. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003;12:320-7.
9. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-53.
10. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-7.
11. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28:1684-91.
12. Goldhirsch A,WoodWC,CoatesAS,GelberRD, Thurlimann B,SennHJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011;22:1736-47.
13. Yu KD, Huang AJ, Fan L, Li WF, Shao ZM. Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation. Cancer Res 2012;72:408-19.
14. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011;43:309-15.
15. Li Y, Vinckenbosch N, Tian G, Huerta-Sanchez E, Jiang T, Jiang H, et al. Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nat Genet 2010;42:969-72.
16. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012;44:570-4.
17. Jiang YZ, Yu KD, Peng WT, Di GH, Wu J, Liu GY, et al. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nat Commun 2014;5:3802.
18. Li R, Yu C, Li Y, Lam TW, Yiu SM, Kristiansen K, et al. SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics 2009; 25:1966-7.
19. Lai LA, Kostadinov R, Barrett MT, Peiffer DA, Pokholok D, Odze R, et al. Deletion at fragile sites is a common and early event in Barrett's esophagus. Mol Cancer Res 2010;8:1084-94.
20. Amos-Landgraf JM, Kwong LN, Kendziorski CM, Reichelderfer M, Torrealba J, Weichert J, et al. A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proc Natl Acad Sci U S A 2007;104:4036-41.
21. Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 2010;21:961-7.
22. Yu KD, Liu GY, Zhou XY, Zhou Y, Wu J, Chen CM, et al. Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane- containing chemotherapy sensitivity in locally advanced breast cancer. Oncologist 2012;17:792-800.
23. Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 2011;11:248.
24. Tong L, Yang XX, Liu MF, Yao GY, Dong JY, Ye CS, et al. Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. Asian Pac J Cancer Prev 2012;13:5599-603.
25. Hao XD, Yang Y, Song X, Zhao XK,WangLD,He JD, et al.Correlation of telomere length shortening with TP53 somatic mutations, polymorphisms and allelic loss in breast tumors and esophageal cancer. Oncol Rep 2013;29:226-36.
26. Fukushima T, Onda M, Abe R, Otake T, Kimijima I, Tsuchiya A. p53 mutations and overexpressions in Japanese breast cancer. Eur J Surg Oncol 1995;21:595-600.
27. Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol 2012;227:42-52.
28. Kalinsky K, Heguy A, Bhanot UK, Patil S, Moynahan ME. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat 2011;129:635-43.
29. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23.
30. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9:701-13.
31. Lehmann BD, Pietenpol JA. Targeting mutant p53 in human tumors. J Clin Oncol 2012;30:3648-50.
32. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del GM, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007;13:6064-9.
33. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30.
34. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-9.
35. Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 2012;30:3077-83.
36. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.